Company News
Stay informed on the latest announcements, scientific milestones, and collaborative achievements from Medical Affairs 360. This page features recent company news, partner highlights, and key developments across clinical research, medical strategy, and publication activity within the pharmaceutical and biotechnology landscape.
Clinical Development
Medical Affairs 360 Announces Regimmune Poster Presentations at the 2026 Tandem Meeting
Medical Affairs 360 is pleased to announce the acceptance of two scientific posters by Regimmune, Inc. for presentation at the 2026 Tandem Meeting, highlighting advanced clinical evidence and innovative statistical approaches supporting RGI-2001 in GVHD prevention.
Clinical Development
Medical Affairs 360 Supports Regimmune’s Landmark Publication on RGI-2001 in Blood Journal
“We are honored to support Regimmune in achieving this significant milestone,” said Dana Lee, Chief Clinical Development Officer at Medical Affairs 360 LLC. “The publication of this study of RGI‑2001 in Blood underscores the growing importance of immunoregulatory strategies, specifically regulatory T-cells (Tregs), to prevent acute graft-versus-host disease.
Drug Safety Analytics & Pharmacovigilance
Medical Affairs 360 Congratulates Loxo Oncology on Its Acquisition by Eli Lilly
Medical Affairs 360 is proud to congratulate its client partner Loxo Oncology on its $8 billion acquisition by Eli Lilly. Our team supported the development of Vitrakvi®, the first FDA-approved TRK inhibitor, by providing clinical advisory guidance, early-phase research insight, and comprehensive pharmacovigilance support from Phase I through product launch. This milestone underscores the impact of strategic medical and safety leadership in advancing innovative oncology therapies.